These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37898394)

  • 1. Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment.
    Gan X; Wang F; Luo J; Zhao Y; Wang Y; Yu C; Chen J
    Eur J Pharm Sci; 2024 Jan; 192():106624. PubMed ID: 37898394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC).
    Dogheim GM; Amralla MT
    Drug Dev Res; 2023 Jun; 84(4):629-653. PubMed ID: 37020351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating PROTACs Discovery Through a Direct-to-Biology Platform Enabled by Modular Photoclick Chemistry.
    Yan KN; Nie YQ; Wang JY; Yin GL; Liu Q; Hu H; Sun X; Chen XH
    Adv Sci (Weinh); 2024 Jul; 11(26):e2400594. PubMed ID: 38689503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of PROTACs in Hematological Malignancies--Review].
    Jia YN; Mi YC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
    Zhang R; Xie S; Ran J; Li T
    J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
    Vicente ATS; Salvador JAR
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity.
    Zhao C; Chen D; Suo F; Setroikromo R; Quax WJ; Dekker FJ
    Bioorg Chem; 2023 Jul; 136():106546. PubMed ID: 37098288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural product-based PROteolysis TArgeting Chimeras (PROTACs).
    Liu M; Martyn AP; Quinn RJ
    Nat Prod Rep; 2022 Dec; 39(12):2292-2307. PubMed ID: 36196977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review.
    Vicente ATS; Salvador JAR
    Expert Opin Ther Pat; 2023; 33(6):397-420. PubMed ID: 37494069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer.
    Wang P; Zhu H; Liu J; Xie S; Xu S; Chen Y; Xu J; Zhao Y; Zhu Z; Xu J
    Bioorg Chem; 2023 Feb; 131():106327. PubMed ID: 36549254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
    Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
    Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of KRAS
    Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
    Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revolutionizing Human papillomavirus (HPV)-related cancer therapies: Unveiling the promise of Proteolysis Targeting Chimeras (PROTACs) and Proteolysis Targeting Antibodies (PROTABs) in cancer nano-vaccines.
    Mukerjee N; Maitra S; Gorai S; Ghosh A; Alexiou A; Thorat ND
    J Med Virol; 2023 Oct; 95(10):e29135. PubMed ID: 37792364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
    Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
    J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
    Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
    Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
    Sincere NI; Anand K; Ashique S; Yang J; You C
    Molecules; 2023 May; 28(10):. PubMed ID: 37241755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.